One Place Where Less Is Definitely More

Sep 09, 2008

According to recently published work in Nature, the Cancer Genome Atlas has revealed that many tumors are heterogeneous. More mutations might mean more drug targets, says Derek Lowe, but that's not necessarily a good thing, he writes at In the Pipeline.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Billion-Pound Sticking Point

The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.

Advisors Push for More Data

The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.

Moderna Expects Early Trial Data Next Month

The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.

Science Papers Explore Contribution of ANXA11 to ALS, Role of Gut Microbiome in Autism Spectrum Disorder

In Science this week: ANXA11 variants affect calcium homeostasis and stress granule disassembly in ALS, and more.

Menu